GILD Stock: Price, Earnings History and SEC Filings
Gilead Sciences, Inc. (GILD) last traded at $170.68, up 3.06% on the latest session and up 14.5% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $2.55 against an analyst estimate of $2.17, a beat of 17.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
GILD earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $2.55 | $2.17 | +17.51% |
| Jun 2026 | Aug 4, 2026 | $-6.75 | $-7.07 | +4.53% |
| Mar 2026 | May 7, 2026 | $2.03 | $1.89 | +7.41% |
| Dec 2025 | Feb 10, 2026 | $1.86 | $1.83 | +1.64% |
GILD beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How GILD reacts to earnings
Across its last 8 earnings releases, GILD moved 4.1% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | After close | +3.06% |
| 2026-08-04 | After close | -2.58% |
| 2026-05-07 | After close | -2.04% |
| 2026-02-10 | After close | +5.82% |
| 2025-10-30 | After close | +1.14% |
| 2025-08-07 | After close | +8.28% |
| 2025-04-24 | After close | -2.81% |
| 2025-02-11 | After close | +7.46% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
GILD financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $29.4B | $8.5B | $9.5B | 28.9% | $6.78 |
| 2024 | $28.8B | $480M | $10.3B | 1.7% | $0.38 |
| 2023 | $27.1B | $5.7B | $7.4B | 20.9% | $4.50 |
| 2022 | $27.3B | $4.6B | $8.3B | 16.8% | $3.64 |
| 2021 | $27.3B | $6.2B | $10.8B | 22.8% | $4.93 |
| 2020 | $24.7B | $123M | $7.5B | 0.5% | $0.10 |
| 2019 | $22.4B | $5.4B | $8.3B | 24.0% | $4.22 |
| 2018 | $22.1B | $5.5B | $7.5B | 24.7% | $4.17 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for GILD
- 10-Q · Oct 30, 2026
- 8-K · Oct 29, 2026Results of operations, Financial statements and exhibits
- 10-Q · Aug 6, 2026
- 8-K · Aug 4, 2026Results of operations, Financial statements and exhibits
- 8-K · May 20, 2026Material agreement, New financial obligation, Other events
- 424B5 · May 18, 2026
- 424B5 · May 14, 2026
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- 8-K · May 4, 2026Shareholder vote, Financial statements and exhibits
Insider filing activity
GILD insiders filed 18 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
GILD news
- 1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in NovemberNov 1, 2026 · fool.com
- GILD Q3 deep dive: HIV franchise drives growth as policy headwinds loomOct 31, 2026 · finance.yahoo.com
- How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A DecadeOct 30, 2026 · finance.yahoo.com
- Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor ConferencesOct 30, 2026 · finance.yahoo.com
- What Just Happened To Alnylam Stock?Oct 30, 2026 · trefis.com
- Gilead's HIV Franchise Supports Growth Outlook, RBC SaysOct 30, 2026 · finance.yahoo.com
- Gilead (GILD) Q3 2026 Earnings Call TranscriptOct 30, 2026 · fool.com
- GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales GrowthOct 30, 2026 · finance.yahoo.com
About Gilead Sciences, Inc.
Gilead Sciences, Inc. (GILD) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.